Cancer Marker Profile - Colorectal

Colorectal cancer is a common type of cancer that affects the colon or rectum and often develops gradually, sometimes without noticeable symptoms in the early stages. Early detection plays a critical role in improving outcomes, as treatment is more effective when the disease is identified at an early or localized stage.

The Cancer Marker Profile - Colorectal is a focused panel that evaluates tumor markers and gastrointestinal bleeding that may be associated with colorectal cancer. This panel includes the CEA (carcino embryonic antigen) test, which is a well-established marker in colorectal cancer care, primarily used to assess tumor burden, monitor response to treatment, and detect recurrence, though it has limited sensitivity for early diagnosis and may be elevated in smokers or benign conditions, such as inflammatory bowel disease, pancreatitis, liver disease (including cirrhosis), hepatitis, and chronic obstructive pulmonary disease (COPD), which can limit its specificity for cancer detection.. 

CA 19.9 supports the assessment of gastrointestinal malignancies and is useful for monitoring disease progression or treatment response, but it lacks specificity for colorectal cancer and is not suitable as a standalone screening test. Levels may also be elevated in benign conditions such as pancreatitis, cholestasis, and liver disease, and some individuals (Lewis antigen–negative) do not produce CA 19.9, which can lead to false-negative results

In addition, the Stool for Occult Blood test detects hidden (microscopic) blood in stool, which can be an early sign of colorectal tumors or polyps. However, the test does not identify the exact source of bleeding and may also be positive in benign conditions such as hemorrhoids, gastrointestinal inflammation, or ulcers. Additionally, certain foods (e.g., red meat, turnips, radishes, broccoli, cauliflower) and some medications may cause false-positive results, so these are often advised to be avoided before sample collection.

A doctor may suggest this panel for individuals undergoing evaluation for colorectal cancer risk, those with suspicious gastrointestinal findings, or patients requiring baseline or follow-up monitoring during or after cancer treatment. 

For this test, provide a brief clinical history or doctor’s prescription at the time of sample collection. For stool occult blood, collect a fresh stool sample in a clean, sterile, leak-proof screw-capped container, taking only a small portion (5–10 g or 1–2 teaspoons) without overfilling. Do not use paper, matchboxes, or absorbent materials, and avoid contamination with urine or water. Avoid painkillers, iron tablets, vitamin C (ascorbic acid), and hard toothbrush use for 3 days before sample collection. Red meat and raw vegetables such as broccoli, cauliflower, radish, and turnip should also be avoided during this period.

Test results should always be interpreted by a doctor along with clinical findings, imaging studies, and, if required, endoscopic evaluation. Based on the results, further diagnostic tests or follow-up monitoring may be recommended.